When people use a combination of HIV prevention methods, researchers found there was a significant drop in HIV transmission.
Published in the academic journal HIV Medicine, the study found that using several methods such as taking PrEP, early HIV diagnosis from frequent testing, and proper antiretroviral treatment decreased transmission by 80 percent.
The research was evaluated at 56 Dean Street, which is a sexual health clinic and part of Chelsea and Westminster Hospital NHS Foundation Trust in London.
“We witnessed an 80% reduction in the number of HIV diagnoses between 2012 and 2017, following the introduction of a number of HIV prevention measures (PrEP introduction, early HIV diagnosis through frequent and facilitated access to HIV testing and timely ART used as treatment-as-prevention) were key to the success of this model,” lead author Nicolo Girometti, told Contagion. Girometti is also a consultant in HIV medicine at 56 Dean Street.
The HIV Age Positively: A Social Work Response Initiative seeks to address the unique challenges experienced by individuals aging with HIV & AIDS. As we strive to identify and enhance social work practices especially to address the unique challenges experienced by those aging with HIV/AIDS, we would like to know more about your experiences, thoughts, and needs as a social work or allied professional working with aging adults living with HIV and/or AIDS.
We invite you to complete and share the online Social Workers Helping Older Adults with HIV Survey. The survey will remain open until Thursday, June 3, 2021. To thank you for your participation, we will be including you in a drawing for a free membership to PASWHA and a conference registration to the National Conference on Social Work and HIV and AIDS.
Additionally, at the end of the survey, you will also be invited to participate in the Client Survey, which will aid us to learn directly about the needs of aging adults living with HIV and/or AIDS.
If you have any questions about the initiative or the survey, please contact Rusty Bennett via email (email@example.com) or phone (205-939-0411) Rusty Bennett.
Stigma and discrimination, such as homophobia and racism, impede engagement in HIV prevention and use of biomedical tools for treatment in both HIV-negative and HIV-positive gay and bisexual men, according to a Rutgers study.
The paper, published in AIDS and Behavior, examined the impact of stigma on HIV-related outcomes among gay and bisexual men in the U.S.
Despite recent advances in HIV prevention and treatment, and access to biomedical interventions that can hasten the end of the HIV epidemic, gay and bisexual men continue to be disproportionately affected by the virus.
This reflection piece details the many challenges and opportunities COVID-19 has brought to the HIV/STD prevention field, particularly in the southern United States, and showcases the innovative approaches sexual health providers implemented to further prevent service disruption.
While the COVID-19 pandemic is still ongoing, this document looks at what the sexual health workforce has been through, and continue to go through, navigating ending an HIV epidemic while in a global pandemic.
Sexually transmitted infections (STIs) impose billions of dollars in medical costs in the U.S., but STI prevention and control is chronically underfunded, stigmatized, and siloed from efforts to promote overall health and well-being, says a new report from the National Academies of Sciences, Engineering, and Medicine. The report calls for modernizing national STI surveillance and monitoring systems, bolstering the STI workforce, developing and scaling up structural and behavioral interventions, and accelerating the development of vaccines, diagnostics, and therapeutics. Taking these strategic actions would also better position the U.S. to respond to COVID-19, HIV/AIDS, and future infectious disease outbreaks, the report says.
Despite the economic burden and alarming increase of STI rates over the last 20 years, the Centers for Disease Control and Prevention’s STI funding has remained flat. Although HIV is an ongoing and highly significant concern, the mandate of the committee that wrote the report was to focus its recommendations on STIs other than HIV, due to increasing rates of chlamydia, gonorrhea, and syphilis. However, the report discusses the interplay between HIV and other STIs, and ways HIV and STI services can collaborate or integrate their prevention, care, and research efforts.
As 2020 draws to a close, we asked David Alain Wohl, M.D., a professor of medicine in the Division of Infectious Diseases at the University of North Carolina and a highly respected HIV clinician-researcher, to take stock of the year’s most momentous research developments and other critical events. In this exclusive series of articles, Wohl calls attention to 10 such developments that have tremendous short-term implications for our day-to-day efforts to improve HIV prevention, treatment, patient care, and policy in the U.S., and analyzes each development with his trademark wit and clinical savvy.
“Looking for something we can rely on. There’s got to be something better out there,” Tina Turner sings in her 1980s pop hit “We Don’t Need Another Hero.” That song jumps into my head when I think about new HIV therapies, but in my mind, it’s framed as a question: Do we need another hero?
For those with few antiretroviral options, who are downing multiple pills to keep multidrug-resistant virus from replicating, the answer would be yes: We do need another antiretroviral hero.
Fortunately, the number of people living with HIV who are heavily treatment experienced and have few remaining antiretroviral options is fairly small. Among over 27,000 HIV-positive people in the U.S. who were treatment experienced and in care at one of the HIV clinics contributing to the U.S. Centers of AIDS Research Network of Integrated Clinical Systems (CNICS) cohort from 2000 to 2017, just 916 had limited treatment options (LTO)—a status defined as having two or fewer available antiretroviral classes, as well as two or fewer active drugs per class as determined by resistance testing. After 2007, the proportion of people with LTO fell; it has since remained less than 1% of the cohort’s antiretroviral experienced patients.
For more than 30 years, Gaétan Dugas was blamed for bringing the AIDS epidemic to the United States. A French-Canadian who died in 1984, Dugas was thought to have carried the disease to America and transmitted it to scores of sexual partners while working as a flight attendant.
But this week, scientists finally cleared the name of the man who, in the history of the AIDS epidemic, came to be known as “Patient Zero.”
In a study published in the journal Nature, the researchers found that blood sampled from Dugas in 1983 contained the same strain of HIV that was infecting men in New York City as early as 1971 — three years before he arrived in the U.S. as an employee for Air Canada.
In 2018, 37,968 people received an HIV diagnosis in the United States (US) and dependent areas. From 2014 to 2018, HIV diagnoses decreased 7% among adults and adolescents. However, annual diagnoses have increased among some groups.
Gay and bisexual men are the population most affected by HIV, with Black/African American, Hispanic/Latino gay and bi men having the highest rates of new infections.
The number of new HIV diagnoses was highest among people aged 25 to 34.
While current antiretroviral treatments for HIV are highly effective, data has shown that people living with HIV appear to experience accelerated aging and have shorter lifespans—by up to five to 10 years—compared to people without HIV. These outcomes have been associated with chronic inflammation, which could lead to the earlier onset of age-associated diseases, such as atherosclerosis, cancers, or neurocognitive decline.
A new study led by researchers at Boston Medical Center examined what factors could be contributing to this inflammation, and they identified the inability to control HIV RNA production from existing HIV DNA as a potential key driver of inflammation. Published in The Journal of Infectious Diseases, the results underscore the need to develop new treatments targeting the persistent inflammation in people living with HIV in order to improve outcomes.
In a 2018 survey of men who have sex with men taking pre-exposure prophylaxis (PrEP) in three U.S. cities, about 10% reported sharing their medication with others.
This finding raises concerns that gay, bisexual and other men who have sex with men (MSM) may be accessing PrEP without receiving the medical monitoring that is supposed to go hand in hand with taking Truvada (tenofovir disoproxil fumarate/emtricitabine) or Descovy (tenofovir alafenamide/ emtricitabine) for HIV prevention—namely, HIV tests every three months and routine screening for sexually transmitted infections and kidney function.
As described in JAMA Network Open, Gordon Mansergh, PhD, a senior behavioral scientist in the Centers for Disease Control and Prevention’s Division of HIV and AIDS Prevention, conducted a cross-sectional analysis of responses from a 2018 smartphone-based survey of 755 HIV-negative MSM living in Detroit, Atlanta and New York.